The expression of this gene might serve as a biomarker of favorable outcome in breast and prostate cancers; conversely, REPS2 downregulation has been demonstrated in the progression of prostate cancer [34, 37–39]. This evidence concerns the gene REPS2 and prostate carcinoma.